Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis

Steven A. Curley, Francesco Izzo, Lee M. Ellis, J. Nicolas Vauthey, Paolo Vallone

Research output: Contribution to journalArticle

676 Citations (Scopus)

Abstract

Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC). Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue beating. Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease. Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69%) and 34 patients (31%), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6%); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45.5%), but 56 patients (50.9%) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7%) after RFA. Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.

Original languageEnglish
Pages (from-to)381-391
Number of pages11
JournalAnnals of Surgery
Volume232
Issue number3
DOIs
Publication statusPublished - 2000

Fingerprint

Liver Neoplasms
Fibrosis
Hepatocellular Carcinoma
Neoplasms
Liver
Recurrence
Laparotomy
Needles
Electrodes
Prospective Studies
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. / Curley, Steven A.; Izzo, Francesco; Ellis, Lee M.; Vauthey, J. Nicolas; Vallone, Paolo.

In: Annals of Surgery, Vol. 232, No. 3, 2000, p. 381-391.

Research output: Contribution to journalArticle

Curley, Steven A. ; Izzo, Francesco ; Ellis, Lee M. ; Vauthey, J. Nicolas ; Vallone, Paolo. / Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. In: Annals of Surgery. 2000 ; Vol. 232, No. 3. pp. 381-391.
@article{916b7bb9834749deb79105f85303958f,
title = "Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis",
abstract = "Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC). Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue beating. Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease. Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69{\%}) and 34 patients (31{\%}), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6{\%}); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45.5{\%}), but 56 patients (50.9{\%}) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7{\%}) after RFA. Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.",
author = "Curley, {Steven A.} and Francesco Izzo and Ellis, {Lee M.} and Vauthey, {J. Nicolas} and Paolo Vallone",
year = "2000",
doi = "10.1097/00000658-200009000-00010",
language = "English",
volume = "232",
pages = "381--391",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis

AU - Curley, Steven A.

AU - Izzo, Francesco

AU - Ellis, Lee M.

AU - Vauthey, J. Nicolas

AU - Vallone, Paolo

PY - 2000

Y1 - 2000

N2 - Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC). Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue beating. Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease. Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69%) and 34 patients (31%), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6%); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45.5%), but 56 patients (50.9%) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7%) after RFA. Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.

AB - Objective: To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC). Summary Background Data: Most patients with HCC are not candidates for resection because of tumor size, location, or hepatic dysfunction related to cirrhosis. RFA is a technique that permits in situ destruction of tumors by means of local tissue beating. Methods: One hundred ten patients with cirrhosis and HCC (Child class A, 50; B, 31; C, 29) were treated during a prospective study using RFA. Patients were treated with RFA using an open laparotomy, laparoscopic, or percutaneous approach with ultrasound guidance to place the RF needle electrode into the hepatic tumors. All patients were followed up at regular intervals to detect treatment-related complications or recurrence of disease. Results: All 110 patients were followed up for at least 12 months after RFA (median follow-up 19 months). Percutaneous or intraoperative RFA was performed in 76 (69%) and 34 patients (31%), respectively. A total of 149 discrete HCC tumor nodules were treated with RFA. The median diameter of tumors treated percutaneously (2.8 cm) was smaller than that of lesions treated during laparotomy (4.6 cm). Local tumor recurrence at the RFA site developed in four patients (3.6%); recurrent HCC subsequently developed in other areas of the liver in all four. New liver tumors or extrahepatic metastases developed in 50 patients (45.5%), but 56 patients (50.9%) had no evidence of recurrence. There were no treatment-related deaths, but complications developed in 14 patients (12.7%) after RFA. Conclusions: In patients with cirrhosis and HCC, RFA produces effective local control of disease in a significant proportion of patients and can be performed safely with minimal complications.

UR - http://www.scopus.com/inward/record.url?scp=0033848847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033848847&partnerID=8YFLogxK

U2 - 10.1097/00000658-200009000-00010

DO - 10.1097/00000658-200009000-00010

M3 - Article

VL - 232

SP - 381

EP - 391

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -